Filing Details

Accession Number:
0001193805-25-000193
Form Type:
13G Filing
Publication Date:
2025-02-13 19:00:00
Filed By:
Schonfeld Strategic Advisors
Company:
Terns Pharmaceuticals Inc.
Filing Date:
2025-02-14
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
Schonfeld Strategic Advisors LLC 0 5,234,508 6.16%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  The percentage of the issuer's common stock beneficially owned by the reporting person reflects 84,938,855 shares of common stock outstanding as of November 8, 2024, as set forth in the Quarterly Report on Form 10-Q filed by the issuer with the Securities and Exchange Commission on November 12, 2024.


SCHEDULE 13G


 
Schonfeld Strategic Advisors LLC
 
Signature:/s/ Mark H. Peckman
Name/Title:Mark H. Peckman/General Counsel and Chief Compliance Officer
Date:02/14/2025